Truvada

Gilead Sciences made $3 billion selling the drug, used to prevent the spread of HIV, last year.
Like any new treatment, there may be misconceptions surrounding PrEP - but if we shy away from discussing it, we are doing a disservice to the thousands of New Yorkers who could benefit from it - particularly those who have a disproportionately higher risk of HIV infection
AIDS guilt for men of my generation isn't a thing so much as it is an implant. We're punished for that too, not by our peers but by our millennial friends, understandably not wishing to be defined by death.
Researchers from the Rollins School of Public Health at Emory University unveiled a new website, www.preplocator.org, that
Unequal use of Truvada may worsen the disparities between races in HIV rates, a study found.
Based on a new case, it is now known that consistent adherence to PrEP might not be enough to protect people from exposure to this particular HIV strain.
n November 2012, writer David Duran penned a piece on Huffington Post challenging the rush to embrace PrEP as a tool to combat